Mad2l1 loss substantially accelerates tumor development in Trp53-positive and/or mutant backgrounds (depending on cell type) emphasizing that checkpoint inactivation and CIN are not just tolerated by cells, they accelerate disease onset in animals already mutant for a potent tumor suppresser. The gene discussed is MAD2L1; the disease is neoplasm.